Statement of India at SCCR 30 on WIPO broadcasting treaty

This is from the statement India read today at SCCR 30, on the topic of the broadcast treaty.

India is flexible in supporting the issue of unauthorized live transmission of signal over computer networks provided the broadcasting organization has rights over the content broadcast by it. India alternative proposals submitted at 26th session of SCCR are in complete conformity with the mandate of the 2007 WIPO General Assembly.

Continue Reading

My question to WIPO, regarding the lack of balance in SCCR 30 presentations on broadcast treaty

Today we are in endless “informational” session, chaired by John Simpson from the BBC, and featuring big broadcasters from India (Zee Network), and Brazil (TV Globo), ABN Holdings Ltd (ABN) (A company headquartered England, about) and the Caribbean Communications Network Limited. Continue Reading

FOIA regarding General Electric’s lobbying of USTR to oppose WIPO Treaty for the Blind.

We just received a reply from a September 17, 2013 FOIA request KEI filed with USTR, asking for correspondence involving General Electric’s efforts to block the WIPO Treaty for the Blind. USTR provided 24 pages of documents, available here:

/wp-content/uploads/FOIA-GE-Treaty-for-Blind.pdf

Continue Reading

Harvey Bale, former Director General of IFPMA, says Fast Track “favors the powerful over the weak”

Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as “A very good day, Indeed.” I asked Dr. Continue Reading

Uncategorized

Put the patents at risk, not the patients

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

Continue Reading

Uncategorized